Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by White, R. R.
Right arrow Articles by Tyler, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by White, R. R.
Right arrow Articles by Tyler, D. S.
Related Collections
Right arrow Chemotherapy
Right arrow Radiation Therapy
Right arrow Surgery
Annals of Surgical Oncology 8:758-765 (2001)
© 2001 Society of Surgical Oncology

ORIGINAL ARTICLES

Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas

Rebekah R. White, MD, Herbert I. Hurwitz, MD, Michael A. Morse, MD, Catherine Lee, MD, Mitchell S. Anscher, MD, Erik K. Paulson, MD, Marcia R. Gottfried, MD, John Baillie, MB, ChB, Malcolm S. Branch, MD, Paul S. Jowell, MB, ChB, Kevin M. McGrath, MD, Bryan M. Clary, MD, Theodore N. Pappas, MD and Douglas S. Tyler, MD

From the Departments of Surgery (RRW, BMC, TNP, DST), Medicine (HIH, MAM, JB, MSB, PSJ, KMM), Radiation Oncology (CL, MSA), Radiology (EKP), and Pathology (MRG); Duke University Medical Center, Durham, North Carolina

Correspondence: Address correspondence and reprint requests to: Douglas S. Tyler, MD, Duke University Medical Center, Box 3118, Durham, NC, 27710; Fax: 919-681-6701; E-mail: tyler002{at}duke.edu

Background: The use of neoadjuvant (preoperative) chemoradiotherapy (CRT) for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors. This article reports our experience with neoadjuvant CRT for localized pancreatic cancer.

Methods: Since 1995, 111 patients with radiographically localized, pathologically confirmed pancreatic adenocarcinoma have received neoadjuvant external beam radiation therapy (EBRT; median, 4500 cGy) with 5-flourouracil–based chemotherapy. Tumors were defined as potentially resectable (PR, n = 53) in the absence of arterial involvement and venous occlusion and locally advanced (LA, n = 58) with arterial involvement or venous occlusion by CT.

Results: Five patients (4.5%) were not restaged due to death (n = 3) or intolerance of therapy (n = 2). Twenty-one patients (19%) manifested distant metastatic disease on restaging CT. Twenty-eight patients with initially PR tumors (53%) and 11 patients with initially LA tumors (19%) were resected after CRT. Histologic examination revealed significant fibrosis in all resected specimens and two complete responses. Surgical margins were negative in 72%, and lymph nodes were negative in 70% of resected patients. Median survival in resected patients has not been reached at a median follow-up of 16 months.

Conclusions: Neoadjuvant CRT provided an opportunity for patients with occult metastatic disease to avoid the morbidity of resection and resulted in tumor downstaging in a minority of patients with LA tumors. Survival after neoadjuvant CRT and resection appears to be at least comparable to survival after resection and adjuvant (postoperative) CRT.

Key Words: Neoadjuvant therapy • Chemoradiotherapy • Adenocarcinoma • Pancreas




This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
R. R. White, M. W. Kattan, J. C. Haney, B. M. Clary, T. N. Pappas, D. S. Tyler, and M. F. Brennan
Evaluation of Preoperative Therapy for Pancreatic Cancer Using a Prognostic Nomogram
Ann. Surg. Oncol., November 1, 2006; 13(11): 1485 - 1492.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
P. Massucco, L. Capussotti, A. Magnino, E. Sperti, M. Gatti, A. Muratore, E. Sgotto, P. Gabriele, and M. Aglietta
Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival
Ann. Surg. Oncol., September 1, 2006; 13(9): 1201 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. S. Talamonti, W. Small Jr., M. F. Mulcahy, J. D. Wayne, V. Attaluri, L. M. Colletti, M. M. Zalupski, J. P. Hoffman, G. M. Freedman, T. J. Kinsella, et al.
A Multi-Institutional Phase II Trial of Preoperative Full-Dose Gemcitabine and Concurrent Radiation for Patients With Potentially Resectable Pancreatic Carcinoma
Ann. Surg. Oncol., February 1, 2006; 13(2): 150 - 158.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
T.-Y. Cheng, K. Sheth, R. R. White, T. Ueno, C.-F. Hung, B. M. Clary, T. N. Pappas, and D. S. Tyler
Effect of Neoadjuvant Chemoradiation on Operative Mortality and Morbidity for Pancreaticoduodenectomy
Ann. Surg. Oncol., January 1, 2006; 13(1): 66 - 74.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
G. Y. Yang, T. D. Wagner, M. Fuss, and C. R. Thomas Jr.
Multimodality Approaches for Pancreatic Cancer
CA Cancer J Clin, November 1, 2005; 55(6): 352 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
H. Ohigashi, O. Ishikawa, H. Eguchi, Y. Sasaki, T. Yamada, S. Noura, K. Murata, K. Takachi, I. Miyashiro, Y. Doki, et al.
Feasibility and Efficacy of Combination Therapy With Preoperative and Postoperative Chemoradiation, Extended Pancreatectomy, and Postoperative Liver Perfusion Chemotherapy for Locally Advanced Cancers of the Pancreatic Head
Ann. Surg. Oncol., August 1, 2005; 12(8): 629 - 636.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y. J. Chua and D. Cunningham
Adjuvant Treatment for Resectable Pancreatic Cancer
J. Clin. Oncol., July 10, 2005; 23(20): 4532 - 4537.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. M. Weber
Histological and Molecular Markers for Pancreatic Adenocarcinoma: Can They Help Us Define Which Patients Should Receive It?
Ann. Surg. Oncol., March 1, 2005; 12(3): 200 - 201.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. R. White, H. B. Xie, M. R. Gottfried, B. G. Czito, H. I. Hurwitz, M. A. Morse, G. C. Blobe, E. K. Paulson, J. Baillie, M. S. Branch, et al.
Significance of Histological Response to Preoperative Chemoradiotherapy for Pancreatic Cancer
Ann. Surg. Oncol., March 1, 2005; 12(3): 214 - 221.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. H. Muler, C. J. McGinn, D. Normolle, T. Lawrence, D. Brown, G. Hejna, and M. M. Zalupski
Phase I Trial Using a Time-to-Event Continual Reassessment Strategy for Dose Escalation of Cisplatin Combined With Gemcitabine and Radiation Therapy in Pancreatic Cancer
J. Clin. Oncol., January 15, 2004; 22(2): 238 - 243.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. V. Gold, K. Schutsky, D. Modrak, and T. M. Cardillo
Low-Dose Radioimmunotherapy (90Y-PAM4) Combined with Gemcitabine for the Treatment of Experimental Pancreatic Cancer
Clin. Cancer Res., September 1, 2003; 9(10): 3929S - 3937.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. F. Kalady, B. M. Clary, L. A. Clark, M. Gottfried, E. M. Rohren, R. E. Coleman, T. N. Pappas, and D. S. Tyler
Clinical Utility of Positron Emission Tomography in the Diagnosis and Management of Periampullary Neoplasms
Ann. Surg. Oncol., October 1, 2002; 9(8): 799 - 806.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. A. Wolff
Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas: Great Logic, Grim Reality
Ann. Surg. Oncol., December 1, 2001; 8(10): 747 - 748.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Society of Surgical Oncology.